
## Donghoon Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5981098/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nature Medicine, 2018, 24, 931-938.	15.2	712
2	Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons. Cell Stem Cell, 2016, 19, 248-257.	5.2	628
3	Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science, 2016, 353, .	6.0	521
4	Graphene quantum dots prevent α-synucleinopathy in Parkinson's disease. Nature Nanotechnology, 2018, 13, 812-818.	15.6	339
5	Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nature Neuroscience, 2013, 16, 1392-1400.	7.1	182
6	α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Molecular Neurodegeneration, 2018, 13, 1.	4.4	143
7	GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 798-803.	3.3	139
8	Activation of tyrosine kinase c-Abl contributes to α-synuclein–induced neurodegeneration. Journal of Clinical Investigation, 2016, 126, 2970-2988.	3.9	133
9	Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease. Acta Neuropathologica Communications, 2021, 9, 78.	2.4	82
10	The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model. Human Molecular Genetics, 2018, 27, 2344-2356.	1.4	55
11	Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease. Brain, 2019, 142, 2380-2401.	3.7	46
12	D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model. Acta Neuropathologica Communications, 2018, 6, 32.	2.4	26
13	TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease. Neuron, 2021, 109, 3758-3774.e11.	3.8	26
14	Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in α-Synuclein-Based Mouse Models of Parkinson's Disease. Journal of Proteome Research, 2021, 20, 3428-3443.	1.8	21
15	Amyloid-like oligomerization of AIMP2 contributes to α-synuclein interaction and Lewy-like inclusion. Science Translational Medicine, 2020, 12, .	5.8	14
16	Estrogen receptor activation contributes to RNF146 expression and neuroprotection in Parkinson's disease models. Oncotarget, 2017, 8, 106721-106739.	0.8	13
17	Lysosomal Enzyme Glucocerebrosidase Protects against Aβ1-42 Oligomer-Induced Neurotoxicity. PLoS ONE, 2015, 10, e0143854.	1.1	12
18	Pyruvate Dehydrogenase Kinase Protects Dopaminergic Neurons from Oxidative Stress in Drosophila DJ-1 Null Mutants. Molecules and Cells, 2022, 45, 454-464.	1.0	6